The Antibody Society Webinars

 

The Antibody Society hosts webinars on a variety of topics that relate to the research and development of antibodies.

Antibodies to Watch webinars provide timely updates on events related to antibody therapeutics in late-stage development and regulatory review, and those that were recently approved.

 

The On Demand webinars #1-10 comprise our Antibody Validation Webinar Series, which is hosted by Dr. Simon Goodman and aimed especially at those beginning a career in biological sciences. In this series, leaders in antibody research from industry and academia reflect on antibody validation.

Webinars
Collapse #14 Delivering therapeutic mAbs for COVID-19: What can be done in just one year?

Accelerating the timeline from biopharmaceutical discovery to clinical evaluation has long been a focus for industry. For potentially life-saving therapies, the earliest clinical testing enables accelerated pivotal trials and maximum patient benefit. In 2020, novel discovery and development strategies have rapidly evaluated antibodies for passive immunization or treatment of COVID-19, employing CMC timelines from lead identification to clinic cut in half. These strategies combine the latest advances in established platforms with acceptance of higher business risk or costs, while ensuring no increased patient risk. But speed to clinic for COVID-19 antibody therapies must be matched by speed to launch and immediate ramp-up in supply to realize a meaningful impact on the global pandemic. Parallel workflows must be initiated at the onset for process and product development as well as cGMP manufacturing. The initial focus on speed to clinic complements a slower approach to development of the most productive commercial cell line, efficient manufacturing process and optimal drug product configuration. Rapid production of initial clinical material followed by pivotal and commercial production arising from cell line, process and formulation optimization emphasizes the importance of product comparability, structure/function knowledge and appropriate control strategies. Meanwhile, scale-up and technology transfer to large manufacturing facilities starts before the first patient is dosed. These strategies impact the program’s technical and regulatory risk profiles, staff and capital resourcing, and set up trade-offs in multiple areas. This case study describes the development history of a COVID-19 antibody, reviewing CMC milestones from lead identification to preparation of the commercial license application as well as plans for post-licensure opportunities, all in one year.

Formats Available: Webinar
Original Seminar Date: May 20, 2021
On-Demand Release Date: May 20, 2021
Register HereRegister Here #14 Delivering therapeutic mAbs for COVID-19: What can be done in just one year?
On-Demand
Collapse The AIRR Community Data Commons: 4 billion reasons to store, analyze and share antibody/B-cell and T-cell receptor repertoire data (On Demand)

The adaptive immune system has evolved a unique molecular diversification mechanism designed to produce a highly diverse set of antigen receptors, necessary to recognize and remove the ever-changing array of pathogens an individual will encounter during their lifetime (e.g., novel coronaviruses). The sheer immensity of each individuals Adaptive Immune Receptor Repertoires (antibody/B-cell and T-cell sequences, or AIRR-seq data) present challenges for producing, storing, sharing, and analyzing these data. The AIRR Community is a group of immunogeneticists, bioinformaticians, and experts in ethics and legal issues of data sharing who joined together to develop standards and protocols for sharing and analyzing these data. Two products of the AIRR-C are the miAIRR standards for storing AIRR-seq data in a common format, and the AIRR Data Commons (ADC), a set of geographically distributed repositories of AIRR-seq data, all adopting these community standards. We are dedicated to the belief that sharing these AIRR-seq data through the AIRR Data Commons will greatly increase their utility for biomedical research and patient care.

The ADC Webinar will discuss the benefits to openly sharing and analyzing these data in an interoperable manner, including access to the >4 billion receptor rearrangements presently queryable through the ADC. We will present demos of how to add your data to the ADC, how to query data through VDJServer and the iReceptor Gateway and preview upcoming analysis tools and repositories being added to the ADC. We will include plenty of time for questions and answers from the audience, and look forward to explaining this ever-expanding resource to our community.

Formats Available: On-Demand
Original Seminar Date: May 04, 2021
Register HereRegister Here The AIRR Community Data Commons: 4 billion reasons to store, analyze and share antibody/B-cell and T-cell receptor repertoire data (On Demand)
Collapse Steps in data processing and analysis of adaptive immune receptor repertoires: best practices, pitfalls, and future directions (On Demand)

High-throughput sequencing has enabled the capture of adaptive immune receptor repertoire (AIRR) data at unprecedented depth and precision. This webinar will give an in-depth walk-through of best practices to conceive, analyze and perform AIRR studies for answering fundamental immunological questions as well as discovering novel immunodiagnostic biomarkers and design (therapeutic) immune receptors. Specifically, Dr. Greiff will address current approaches to perform AIRR-compliant AIRR data processing encompassing bulk and single-cell approaches and experimental and bioinformatics quality control. Furthermore, he will summarize the computational methods that have been recently developed to deconstruct the high-dimensional complexity of immune receptor repertoires, e.g., 1) diversity-, 2) phylogenetic-, 3) networks- and 4) machine learning-based methods that have been applied to dissect and understand the diversity, architecture, evolution and antigen specificity of immune repertoires. Finally, Dr. Greiff will discuss experimental and computational methods in light of their underlying assumptions, limitations and pitfalls and highlight promising avenues of future research in basic and applied AIRR systems immunology.

Formats Available: On-Demand
Original Seminar Date: April 06, 2021
On-Demand Release Date: Available Now
Register HereRegister Here Steps in data processing and analysis of adaptive immune receptor repertoires: best practices, pitfalls, and future directions (On Demand)
Collapse #13 - Deep mining of early antibody response in COVID-19 patients yields potent neutralizers and reveals high level of convergence (On Demand)

In this webinar, Dr. John McCafferty presents results from the deep-mining of the antibody repertoires of hospitalized COVID-19 patients using a combination of phage display technology and B cell receptor repertoire sequencing to isolate neutralizing antibodies and gain insights into the early antibody response. This comprehensive discovery approach yielded potent neutralizing antibodies with distinct mechanisms of action. In particular, a novel non-ACE2 receptor blocking antibody that is not expected to be affected by any of the major viral variants reported was identified. Potent neutralizing antibodies with near germline sequences within both the IgG and IgM pools at early stages of infection were also found. The study results highlight a highly convergent antibody response with the same sequences occurring both within this patient group and within the responses described in previously published anti-SARS-CoV-2 antibody studies.

Formats Available: On-Demand
Original Seminar Date: March 18, 2021
Register HereRegister Here #13 - Deep mining of early antibody response in COVID-19 patients yields potent neutralizers and reveals high level of convergence (On Demand)
Collapse #12 - Ultra-fast development of an anti-COVID-19 antibody (On Demand)

The SARS-CoV-2 pandemic has spread all over the world in the past year and there is still no efficient treatment available for COVID-19, particularly for patients undergoing severe courses, which often lead to fatal consequences. Antiviral drugs such as virus-neutralizing antibody therapeutics are still urgently needed to save millions of lives. Corat Therapeutics developed a novel SARS-CoV-2 neutralizing, fully human antibody derived from convalescent patients. Ultra-fast development strategies shortened timelines from discovery to GMP manufactured material to less than 8 months. This was possible by parallelizing discovery and development steps, as well as performing crucial steps on risk. First-in-human studies were recently initiated. This webinar gives an overview of the challenges faced during discovery and development of the lead antibody, COR-101.

Formats Available: On-Demand, Live Webcast
Original Seminar Date: February 18, 2021
On-Demand Release Date: Available Now
Register HereRegister Here #12 - Ultra-fast development of an anti-COVID-19 antibody (On Demand)
Collapse #11 - Antibody Discovery in the Cloud: Using NGS to expand the universe of selectable antibodies (On Demand)
Antibody Discovery and Development (1)

The Specifica Generation 3 platform is able to generate 500-5000 different antibody clonotypes against targets of interest, with over 80% of selected antibodies having no measurable biophysical liabilities and 20% having subnanomolar affinities. The most common approach to selecting antibodies from display technologies involves low-throughput random colony screening. However, this misses many potential therapeutic leads, particularly when diversity is high. Specifica uses next generation sequencing (NGS) to build its libraries as well as characterize selection outputs. In order to fully exploit the universe of selectable antibodies, Specifica has developed a cloud-based software platform, designed exclusively for antibody engineers and bioinformaticians, to enable a streamlined identification of leads with broad epitope coverage. Application of this to selection outputs has increased the number of clonotype leads by five to ten fold over random colony screening, significantly expanding the explorable paratope space.

Formats Available: On-Demand, Live Webcast
Original Seminar Date: January 21, 2021
Register HereRegister Here #11 - Antibody Discovery in the Cloud: Using NGS to expand the universe of selectable antibodies (On Demand)
Collapse Antibodies to Watch in 2021 (On Demand)

The COVID-19 pandemic has presented many challenges to the biopharmaceutical industry. Initiating programs to discover and develop new antibodies that targeted SARS-CoV-2 was critical, but at the same time, programs bringing existing investigational therapies through late-stage clinical studies and regulatory review also needed to be maintained.

Dr. Janice Reichert (The Antibody Society) provides an update on antibody therapeutics approved in the US and European Union during 2020, those that may be approved by the end of 2021, and those that might enter regulatory review in the US or EU soon. She will also discuss current and potential emergency use authorizations for anti-SARS-CoV-2 antibodies.

Dr. Nick Hutchinson (FUJIFILM Diosynth Biotechnologies) discusses how the pandemic has driven scientists and engineers to find new ways to leverage antibody production capacity most effectively in order to meet the need for rapid early phase development, as well as high-demand commercial manufacturing and what this may mean for antibody manufacturing strategies in the future.

Formats Available: On-Demand, Live Webcast
Original Seminar Date: December 03, 2020
Register HereRegister Here Antibodies to Watch in 2021 (On Demand)
Collapse Antibodies to Watch in a Pandemic (On Demand)

The extraordinary scope and scale of the COVID-19 pandemic has elicited extraordinary responses world-wide. Organizations located across the globe have mobilized teams to research the SARS-CoV-2 virus and COVID-19, conduct clinical studies of repurposed biologics, and research and develop anti-SARS-CoV-2 biologics. Disruptions at companies and regulatory agencies, however, have raised concerns about the effects of the pandemic on possible approvals of non-COVID-19 antibody therapeutics. In a series of webinars, The Antibody Society will report on important developments in the commercial pipeline of antibody therapeutics for COVID-19, as well as other indications.

In “Antibodies to Watch in a Pandemic”, Dr. Janice Reichert (The Antibody Society) provides an update on non-COVID-19 antibody therapeutics approved in the first half of 2020, and those that might be approved by the end of the year. She also discusses the ~ 130 biologics currently in development for COVID-19, which includes over 50 repurposed biologics and over 80 anti-SARS-CoV-2 biologics. Additionally, Dr. Thomas Schirrmann (Yumab) presents a case study of how to develop anti-SARS-CoV-2 antibodies in both academic and industrial settings.

Formats Available: On-Demand
Original Seminar Date: June 30, 2020
On-Demand Release Date: Available Now
Register HereRegister Here Antibodies to Watch in a Pandemic (On Demand)
Collapse #10 - Specific Detection Reagents: What
The Antibody Society's Webcast series on Antibody Validation

Future recombinant binding tools may avoid antibodies, and use diversified libraries based on small and versatile protein scaffolds, for example the DARPins (Designed Ankyrin Repeat Proteins).  DARPins are single-chain, monodisperse, and non-immunogenic, and can be made rapidly and cheaply in bacteria in many formats.  They can also be expressed in and on cells as non-aggregating fusion proteins with tunable valencies, which opens a wide range of previously inaccessible approaches in cell biology and biochemistry.

Formats Available: On Demand
Original Seminar Date: February 19, 2020
Register HereRegister Here #10 - Specific Detection Reagents: What
Collapse  #9 - Getting to Recombinant Antibodies that Guarantee Reproducible Research (On-Demand)
The Antibody Society's Webcast series on Antibody Validation

Dr. Andrew Bradbury, Specifica, suggests ways out of the validation maze by rigorous molecular identification of recombinant tool antibodies. This achievable goal could eliminate many of the shadowy issues described in this series of webinars.

Formats Available: On Demand
Original Seminar Date: February 12, 2020
Register HereRegister Here  #9 - Getting to Recombinant Antibodies that Guarantee Reproducible Research (On-Demand)
Collapse #8 - Protein Arrays and Mass Spectrometry (On-Demand)
The Antibody Society's Webcast series on Antibody Validation

Dr. Mike Taussig, Cambridge Protein Arrays, and Dr. Fridtjof Lund-Johansen, Oslo University Hospital, look at array and immunoprecipitation-mass spectrometry technologies, which offer a broader and deeper image of antibody specificity and selectivity for validation, than classical validation technologies.

Formats Available: On Demand
Original Seminar Date: February 05, 2020
Register HereRegister Here #8 - Protein Arrays and Mass Spectrometry (On-Demand)
Collapse #7 - It
The Antibody Society's Webcast series on Antibody Validation

Dr. Travis Hardcastle, Horizon, and Dr. Alejandra Solache, Abcam, describe the character of different gene-knockout technologies, one of the strongest validation technologies, and their value in large-scale antibody screening. 

Formats Available: On Demand
Original Seminar Date: January 29, 2020
Register HereRegister Here #7 - It
Collapse #6 - Even the easy stuff isn
The Antibody Society's Webcast series on Antibody Validation

Professors Aldrin Gomes and James Trimmer, both from University of California, Davis, dissect two “basic” validation technologies, Western blot and immunohistochemistry, to expose the very many things that can distort validation data.

Formats Available: On Demand
Original Seminar Date: January 22, 2020
Register HereRegister Here #6 - Even the easy stuff isn
Collapse #5 - Really? Out of control(s)? (On-Demand)
The Antibody Society's Webcast series on Antibody Validation

Dr. Giovanna Roncador, Centro Nacional de Investigaciones Oncológicas and EuroMabNet, examinesthe criticality ofusing appropriate fit-for-purpose controls, both positive and negative, to validate antibodies in every experimental context.

Formats Available: On Demand
Original Seminar Date: January 15, 2020
Register HereRegister Here #5 - Really? Out of control(s)? (On-Demand)
Collapse #4 - What is this Antibody? (On-demand)
The Antibody Society's Webcast series on Antibody Validation

Professor Anita Bandrowski, University California San Diego and SciCrunch, and Dr. Jan Voskuil, Aeonian Biotech, probe how antibody reagents are identified.  If we can’t identify which antibody has been used, we can never reproduce experiments.  The Research Reagent Identifier systematically tags antibodies so they can be tracked, but the small-print on the data-sheets still hides many things.

Formats Available: On Demand
Original Seminar Date: December 05, 2019
Register HereRegister Here #4 - What is this Antibody? (On-demand)
Collapse #3 - What
The Antibody Society's Webcast series on Antibody Validation

Dr. Jan Voskuil, Aeonian Biotech, and Professor Andy Chalmers, University of Bath and CiteAb, delve into the mysterious world of original equipment manufacturers (OEMs), which can veil the identity of antibodies, and data-base repositories that help unveil which antibody has produced reliable results.

Formats Available: On Demand
Original Seminar Date: December 04, 2019
Register HereRegister Here #3 - What
Collapse #2 - Antibodies drive irreproducibility (On-Demand)
The Antibody Society's Webcast series on Antibody Validation

Professor Glenn Begley, Biocurate Pty Ltd, and Professor Cecilia Williams, KTH  Royal Institute of Technology, describe arduous, alarming and very costly experiences in failing to confirm “well established” critical data in oncology –a failure often driven by ineptly characterized antibodies.

Formats Available: On Demand
Original Seminar Date: November 13, 2019
Register HereRegister Here #2 - Antibodies drive irreproducibility (On-Demand)
Collapse #1 - Antibody specificity? What
The Antibody Society's Webcast series on Antibody Validation

In this introduction to the topic, Professor Andreas Plückthun, University of Zürich, discusses the biology of the 3 principal types of commercial antibodies: polyclonal, monoclonal, and recombinant.  Surprisingly, only recombinants offer a reasonable hope of reproducibility in the long term – yet they remain very much the minority.

Formats Available: On Demand
Original Seminar Date: November 12, 2019
Register HereRegister Here #1 - Antibody specificity? What